References

  1. UNAIDS. Global AIDS Update. 2016. UNAIDS. Accessed: March 25 2018.

  2. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J AIDS (1999). 2000 Jan; 23(1): 35-43. PubMed | Google Scholar

  3. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA. Impact of HIV infection and HAART on serum lipids in men. Jama. 2003 Jun 11; 289(22): 2978-82. PubMed | Google Scholar

  4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999 Jun 19; 353(9170): 2093-9. PubMed | Google Scholar

  5. Sherer R, Solomon S, Schechter M, Nachega JB, Rockstroh J, Zuniga JM. HIV Provider-Patient Communication Regarding Cardiovascular Risk: results from the 2010 AIDS Treatment for Life International Survey. JIAPAC. 2014 Jul; 13(4): 342-5. PubMed | Google Scholar

  6. Bloomfield GS, Khazanie P, Morris A, Rabadán-Diehl C, Benjamin LA, Murdoch D, Radcliff VS, Velazquez EJ, Hicks C. HIV and non-communicable cardiovascular and pulmonary diseases in low-and middle-income countries in the ART era: what we know and best directions for future research. J Acquir Immune Defic Syndr. 2014 Sep 1; 67 Suppl 1: S40-53. PubMed | Google Scholar

  7. Ssinabulya I, Kayima J, Longenecker C, Luwedde M, Semitala F, Kambugu A, Ameda F, Bugeza S, McComsey G, Freers J, Nakanjako D. Subclinical atherosclerosis among HIV-infected adults attending HIV/AIDS care at two large ambulatory HIV clinics in Uganda. PloS one. 2014 Feb 28; 9(2): e89537. PubMed | Google Scholar

  8. Chow D. Epidemiological evidence of increasing blood pressure in HIV-1-infected individuals in the era of HAART. Antiviral Therapy. 2000; 5: P13.

  9. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V. Premature atherosclerosis in HIV-infected individuals?focus on protease inhibitor therapy. AIDS. 2001 Feb 16; 15(3): 329-34. PubMed | Google Scholar

  10. Thiébaut R, El-Sadr WM, Friis-Moller N, Rickenbach M, Reiss P, Monforte AD, Morfeldt L, Fontas E, Kirk O, De Wit S, Calvo G. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral therapy. 2005 Jan 1; 10(7): 811. PubMed | Google Scholar

  11. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS. 2006 Apr 24; 20(7): 1019-26. PubMed | Google Scholar

  12. Ballah Akawu Denue, Pharm Jamil Muazu, Wadzani Gashau, Daniel Nkami MBO, Nnenna Anthony Ajayi. Effects of highly active antiretroviral therapy (HAART) on blood pressure changes and its associated factors in HAART naive HIV-infected patients in North eastern Nigeria. Scholar research library. 2012; 4(3): 1447-1452. Google Scholar

  13. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS. 2001 Oct 19; 15(15): 2001-10. PubMed | Google Scholar

  14. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J hypert. 2003 Jul 1; 21(7): 1377-82. PubMed | Google Scholar

  15. Barbaro G, Klatt EC. HIV infection and the cardiovascular system. Aids Rev. 2002; 4(2): 93-103. PubMed | Google Scholar

  16. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. European J Clin Microbiol & Infect Dises. 2003 Dec 1; 22(12): 731-6. PubMed | Google Scholar

  17. Palacios R, Santos J, Garcia A, Castells E, González M, Ruiz J, Marquez M. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients: a prospective study in a cohort of naive patients. HIV Med. 2006 Jan; 7(1): 10-5. PubMed | Google Scholar

  18. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, Williams CM, Phair JP. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. Aids. 2005 Jun 10; 19(9): 953-60. PubMed | Google Scholar

  19. Arrey WT, Dimala CA, Atashili J, Mbuagbaw J, Monekosso GL. Hypertension, an emerging problem in rural Cameroon: prevalence, risk factors, and control. Inter J hypert. 2016; 2016: 5639146. PubMed | Google Scholar

  20. Cattelan AM, Trevenzoli M, Sasset L, Rinaldi L, Balasso V, Cadrobbi P. Indinavir and systemic hypertension. AIDS. 2001 Apr 13; 15(6): 805-7. PubMed | Google Scholar

  21. De Socio GV, Schillaci G. Hypertension in HIV patients. AIDS. 2006 Aug 1; 20(12): 1682-3. PubMed | Google Scholar

  22. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J of Infect Dis. 2005 Dec 1; 192(11): 1921-30. PubMed | Google Scholar

  23. HIV i-Base. Hypertension related to HAART in HIV-positive women | HTB | HIV i-Base. Accessed: Mar 25 2018.

  24. Muhammad S, Sani MU, Okeahialam BN. Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. Nigerian Med J. 2013 May; 54(3): 185. PubMed | Google Scholar